Pub Date : 2017-08-21DOI: 10.4172/2329-6771.1000196
B. Kash, Molly McKahan, S. Mack, U. Nanda
In selected patients diagnosed with Breast Cancer (BC), adjuvant chemotherapy might reduce local and systemic recurrence risk, as well as cancer death rate. The combination of Docetaxel and Cyclophosphamide (TC) is a wellrecognized effective adjuvant chemotherapy regimen. Nonetheless, a considerable high rate of febrile neutropenia (FN) is associated with this regimen. We sought to investigate hematologic toxicity associated with adjuvant TC in a non-selected, “real world” cohort of BC patients. Methods: We reviewed the electronic medical records of patients who presented to the Oncology Center from Hospital Sirio-Libanes (HSL) and Instituto do Câncer do Estado de Sao Paulo (ICESP). Patients included in the analysis received adjuvant chemotherapy with TC regimen after definitive breast surgery. Results: 95 patients with were included in our analysis. Median age was 55.5 years. All patients had a good performance status (either ECOG 0 or 1), and the great majority had no comorbidities. Most patients received 4 cycles of chemotherapy (80%). Data on granulocyte colony stimulating factor (G-CSF) administration was available in 85 patients from our cohort. G-CSF was used as primary prophylaxis in 31 patients, and as secondary prophylaxis in 13 patients, following a prior episode of febrile neutropenia. Overall, fifteen women (15.8%) had a documented FN episode. Among women who received G-CSF as primary prophylaxis, the rate of FN was 6.45% (2 patients). In contrast, among patients who did not receive primary prophylaxis with G-CSF, FN rate was considerably higher, namely 24.07% (13 patients). Patients who received primary prophylaxis with G-CSF had a statistically significant lower risk of experiencing a FN episode (p=0.049). Conclusion: Febrile Neutropenia rate in this group of non-selected BC patients was higher than previous reported on randomized controlled trials that evaluated adjuvant TC regimen in the same dosing and schedule as used in our cohort. Primary prophylaxis with G-CSF was associated with a statistically significant lower risk of FN and should be considered in the management of patients who receive this chemotherapy combination.
{"title":"Systematic Review of Emerging Models of Cancer Care: Implications for the Health Industry","authors":"B. Kash, Molly McKahan, S. Mack, U. Nanda","doi":"10.4172/2329-6771.1000196","DOIUrl":"https://doi.org/10.4172/2329-6771.1000196","url":null,"abstract":"In selected patients diagnosed with Breast Cancer (BC), adjuvant chemotherapy might reduce local and systemic recurrence risk, as well as cancer death rate. The combination of Docetaxel and Cyclophosphamide (TC) is a wellrecognized effective adjuvant chemotherapy regimen. Nonetheless, a considerable high rate of febrile neutropenia (FN) is associated with this regimen. We sought to investigate hematologic toxicity associated with adjuvant TC in a non-selected, “real world” cohort of BC patients. \u0000Methods: We reviewed the electronic medical records of patients who presented to the Oncology Center from Hospital Sirio-Libanes (HSL) and Instituto do Câncer do Estado de Sao Paulo (ICESP). Patients included in the analysis received adjuvant chemotherapy with TC regimen after definitive breast surgery. \u0000Results: 95 patients with were included in our analysis. Median age was 55.5 years. All patients had a good performance status (either ECOG 0 or 1), and the great majority had no comorbidities. Most patients received 4 cycles of chemotherapy (80%). Data on granulocyte colony stimulating factor (G-CSF) administration was available in 85 patients from our cohort. G-CSF was used as primary prophylaxis in 31 patients, and as secondary prophylaxis in 13 patients, following a prior episode of febrile neutropenia. Overall, fifteen women (15.8%) had a documented FN episode. Among women who received G-CSF as primary prophylaxis, the rate of FN was 6.45% (2 patients). In contrast, among patients who did not receive primary prophylaxis with G-CSF, FN rate was considerably higher, namely 24.07% (13 patients). Patients who received primary prophylaxis with G-CSF had a statistically significant lower risk of experiencing a FN episode (p=0.049). \u0000Conclusion: Febrile Neutropenia rate in this group of non-selected BC patients was higher than previous reported on randomized controlled trials that evaluated adjuvant TC regimen in the same dosing and schedule as used in our cohort. Primary prophylaxis with G-CSF was associated with a statistically significant lower risk of FN and should be considered in the management of patients who receive this chemotherapy combination.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"37 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2017-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86110508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-30DOI: 10.4172/2329-6771.1000195
D. Gagliato, João Paulo Velloso Medrado Santos, R. Cossetti, Rodrigo Darouche Gimenez, A. C. C. D. Gouvêa, M. S. Ferrari, A. Katz, R. Marques, M. Mano
Introduction: In selected patients diagnosed with Breast Cancer (BC), adjuvant chemotherapy might reduce local and systemic recurrence risk, as well as cancer death rate. The combination of Docetaxel and Cyclophosphamide (TC) is a well-recognized effective adjuvant chemotherapy regimen. Nonetheless, a considerable high rate of febrile neutropenia (FN) is associated with this regimen. We sought to investigate hematologic toxicity associated with adjuvant TC in a non-selected, “real world” cohort of BC patients. Methods: We reviewed the electronic medical records of patients who presented to the Oncology Center from Hospital Sirio-Libanes (HSL) and Instituto do Câncer do Estado de Sao Paulo (ICESP). Patients included in the analysis received adjuvant chemotherapy with TC regimen after definitive breast surgery. Results: 95 patients with were included in our analysis. Median age was 55.5 years. All patients had a good performance status (either ECOG 0 or 1), and the great majority had no comorbidities. Most patients received 4 cycles of chemotherapy (80%). Data on granulocyte colony stimulating factor (G-CSF) administration was available in 85 patients from our cohort. G-CSF was used as primary prophylaxis in 31 patients, and as secondary prophylaxis in 13 patients, following a prior episode of febrile neutropenia. Overall, fifteen women (15.8%) had a documented FN episode. Among women who received G-CSF as primary prophylaxis, the rate of FN was 6.45% (2 patients). In contrast, among patients who did not receive primary prophylaxis with G-CSF, FN rate was considerably higher, namely 24.07% (13 patients). Patients who received primary prophylaxis with G-CSF had a statistically significant lower risk of experiencing a FN episode (p=0.049). Conclusion: Febrile Neutropenia rate in this group of non-selected BC patients was higher than previous reported on randomized controlled trials that evaluated adjuvant TC regimen in the same dosing and schedule as used in our cohort. Primary prophylaxis with G-CSF was associated with a statistically significant lower risk of FN and should be considered in the management of patients who receive this chemotherapy combination.
{"title":"Febrile Neutropenia Risk with Adjuvant Docetaxel and Cyclophosphamide (TC) Chemotherapy Regimen in Two Brazilians Cancer Centers","authors":"D. Gagliato, João Paulo Velloso Medrado Santos, R. Cossetti, Rodrigo Darouche Gimenez, A. C. C. D. Gouvêa, M. S. Ferrari, A. Katz, R. Marques, M. Mano","doi":"10.4172/2329-6771.1000195","DOIUrl":"https://doi.org/10.4172/2329-6771.1000195","url":null,"abstract":"Introduction: In selected patients diagnosed with Breast Cancer (BC), adjuvant chemotherapy might reduce \u0000 local and systemic recurrence risk, as well as cancer death rate. The combination of Docetaxel and \u0000 Cyclophosphamide (TC) is a well-recognized effective adjuvant chemotherapy regimen. Nonetheless, a \u0000 considerable high rate of febrile neutropenia (FN) is associated with this regimen. We sought to investigate \u0000 hematologic toxicity associated with adjuvant TC in a non-selected, “real world” cohort of BC patients. \u0000Methods: We reviewed the electronic medical records of patients who presented to the Oncology Center from \u0000 Hospital Sirio-Libanes (HSL) and Instituto do Câncer do Estado de Sao Paulo (ICESP). Patients included in the \u0000 analysis received adjuvant chemotherapy with TC regimen after definitive breast surgery. \u0000Results: 95 patients with were included in our analysis. Median age was 55.5 years. All patients had a good \u0000 performance status (either ECOG 0 or 1), and the great majority had no comorbidities. Most patients received 4 \u0000 cycles of chemotherapy (80%). Data on granulocyte colony stimulating factor (G-CSF) administration was available \u0000 in 85 patients from our cohort. G-CSF was used as primary prophylaxis in 31 patients, and as secondary prophylaxis \u0000 in 13 patients, following a prior episode of febrile neutropenia. Overall, fifteen women (15.8%) had a documented FN \u0000 episode. Among women who received G-CSF as primary prophylaxis, the rate of FN was 6.45% (2 patients). In \u0000 contrast, among patients who did not receive primary prophylaxis with G-CSF, FN rate was considerably higher, \u0000 namely 24.07% (13 patients). Patients who received primary prophylaxis with G-CSF had a statistically significant \u0000 lower risk of experiencing a FN episode (p=0.049). \u0000Conclusion: Febrile Neutropenia rate in this group of non-selected BC patients was higher than previous \u0000 reported on randomized controlled trials that evaluated adjuvant TC regimen in the same dosing and schedule as \u0000 used in our cohort. Primary prophylaxis with G-CSF was associated with a statistically significant lower risk of FN \u0000 and should be considered in the management of patients who receive this chemotherapy combination.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"38 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72849330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-30DOI: 10.4172/2329-6771.1000194
Oroma Beatrice Nwanodi
Background: Homeopathy is used by 12 to 24% of European cancer patients, representing 40.4% of patients at European integrative cancer centers. In 2011, a Swiss literature review on homeopathy led to homeopathic treatment coverage in the Swiss national health insurance program. Homeopathy for curative pediatric cancer treatment is limited to 7.4% in the Netherlands, but, 76.5% of German parents will use homeopathy as part of their children’s cancer treatment. The purpose of this paper is to determine what is needed for homeopathy to play a larger role in curative, concurrent, and supportive cancer treatment. Methods: PubMed searches in September 2016 and January 2017 were performed with search terms “adverse effects, breast cancer, cancer, cervical cancer, endometrial cancer, homeopathy, ovarian cancer, prevention, treatment”. Curative, concurrent, and supportive homeopathic cancer treatments material was taken from these searches. Findings: At least five homeopathic formulations are immunologic adjuvants, activating natural killer cell destruction of cancer and virally infected cells. Ultramolecular Carcinosin, Phytolacca decandra, Conium, Thuja and Klimaktoplan® are appropriate for in vivo breast cancer trials. Lycopodium clavatum 5C and 15C are ready for in vivo cervical cancer trials. Sulphur 30C, may be considered for non-small cell lung adenocarcinoma treatment trials. Conventional cancer treatment associated anxiety, asthenia, depression, dermatitis, folliculitis, hot flushes, insomnia, nausea and vomiting, and stomatitis, respond to numerous homeopathic treatments including hetero-isotherapy. Conclusion & Significance: In vitro studies and retrospective case series indicate that homeopathy could provide curative cancer treatment for an array of cancers: Breast, cervix, gallbladder, liver, lung, oral, pancreas, periampullary, skin, and stomach. Appropriately designed randomized controlled trials (RCT) based on reproducible homeopathic treatments and clinical protocols, with intent-to-treat analysis will have increased validity. If these RCT have positive outcomes homeopathy will secure a position in curative, concurrent, and supportive cancer treatment.
{"title":"Homeopathy: Curative, Concurrent and Supportive Cancer Treatment Potential","authors":"Oroma Beatrice Nwanodi","doi":"10.4172/2329-6771.1000194","DOIUrl":"https://doi.org/10.4172/2329-6771.1000194","url":null,"abstract":"Background: Homeopathy is used by 12 to 24% of European cancer patients, representing 40.4% of patients at European integrative cancer centers. In 2011, a Swiss literature review on homeopathy led to homeopathic treatment coverage in the Swiss national health insurance program. Homeopathy for curative pediatric cancer treatment is limited to 7.4% in the Netherlands, but, 76.5% of German parents will use homeopathy as part of their children’s cancer treatment. The purpose of this paper is to determine what is needed for homeopathy to play a larger role in curative, concurrent, and supportive cancer treatment. \u0000Methods: PubMed searches in September 2016 and January 2017 were performed with search terms “adverse effects, breast cancer, cancer, cervical cancer, endometrial cancer, homeopathy, ovarian cancer, prevention, treatment”. Curative, concurrent, and supportive homeopathic cancer treatments material was taken from these searches. \u0000Findings: At least five homeopathic formulations are immunologic adjuvants, activating natural killer cell destruction of cancer and virally infected cells. Ultramolecular Carcinosin, Phytolacca decandra, Conium, Thuja and Klimaktoplan® are appropriate for in vivo breast cancer trials. Lycopodium clavatum 5C and 15C are ready for in vivo cervical cancer trials. Sulphur 30C, may be considered for non-small cell lung adenocarcinoma treatment trials. Conventional cancer treatment associated anxiety, asthenia, depression, dermatitis, folliculitis, hot flushes, insomnia, nausea and vomiting, and stomatitis, respond to numerous homeopathic treatments including hetero-isotherapy. \u0000Conclusion & Significance: In vitro studies and retrospective case series indicate that homeopathy could provide curative cancer treatment for an array of cancers: Breast, cervix, gallbladder, liver, lung, oral, pancreas, periampullary, skin, and stomach. Appropriately designed randomized controlled trials (RCT) based on reproducible homeopathic treatments and clinical protocols, with intent-to-treat analysis will have increased validity. If these RCT have positive outcomes homeopathy will secure a position in curative, concurrent, and supportive cancer treatment.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"16 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84579374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-01DOI: 10.4172/2329-6771.1000214
Tadesse Bedada, Haregewoin Ayalew Teshale, A. Hailu, Tefera Mulugeta
A THESIS SUBMITTED TO THE SCHOOL OF GRADUATE STUDIES ADDIS ABABA UNIVERSITY COLLEGE OF HEALTH SCIENCE SCHOOL OF ALLIED HEALTH SCIENCES DEPARTMENT OF NURSING AND MIDWIFERY IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER IN ONCOLOGY NURSING
{"title":"Prevalence and Factors Contributing to Late Diagnosis of Breast Cancer among Women Attending Tikur Anbessa Specialized Hospital, Oncology Unit, Addis Ababa, Ethiopia, 2017","authors":"Tadesse Bedada, Haregewoin Ayalew Teshale, A. Hailu, Tefera Mulugeta","doi":"10.4172/2329-6771.1000214","DOIUrl":"https://doi.org/10.4172/2329-6771.1000214","url":null,"abstract":"A THESIS SUBMITTED TO THE SCHOOL OF GRADUATE STUDIES ADDIS ABABA UNIVERSITY COLLEGE OF HEALTH SCIENCE SCHOOL OF ALLIED HEALTH SCIENCES DEPARTMENT OF NURSING AND MIDWIFERY IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER IN ONCOLOGY NURSING","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"201 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75985926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-05-30DOI: 10.4172/2329-6771.1000193
Dorsaf Bengaied, A. Ribeiro, M. Amri, D. Scherman, P. Arnaud
Doxorubicin (DOX) has been used in the treatment of variety of cancers but its administration is limited by a dosedependent toxicity. Its cytotoxic effects on malignant cells have shown an increase in the risk of cardiotoxicity, hepatoxicity, renal insufisance. Antioxydants have been explored for both their cancer preventive properties and chemodulatory of DOX toxicity. Resveratrol (RSV) is a polyphenolic constituent of several dietary mainly of grapes and wine origin recently its anticancer potential has been extensively explored, revealing its anti-proliferative effect on different cancer cell lines, both in vitro and in vivo. RSV is also known to have modulatory effects on cell apoptosis, migration and growth via various signaling pathways. Though, RSV possesses great medicinal value, its applications as a therapeutic drug is limited. Problems like low oral bioavailability and poor aqueous solubility make RSV an unreliable candidate for therapeutic purposes. Additionally, the rapid gastrointestinal digestion of RSV is also a major barrier for its clinical translation. Hence, to overcome these disadvantages RSV-based nanodelivery systems have been considered in recent times. Nanodelivery systems of RSV have shown promising results in its uptake by the epithelial system as well as enhanced delivery to the target site. Herein we have tried to bring new new insights into the molecular mechanisms of DOX toxicity with respect to DNA damage, free radicals and whether RSV can be a playmaker as chemodulatory of DOx.
{"title":"Reduction of Hepatotoxicity Induced by Doxorubicin","authors":"Dorsaf Bengaied, A. Ribeiro, M. Amri, D. Scherman, P. Arnaud","doi":"10.4172/2329-6771.1000193","DOIUrl":"https://doi.org/10.4172/2329-6771.1000193","url":null,"abstract":"Doxorubicin (DOX) has been used in the treatment of variety of cancers but its administration is limited by a dosedependent toxicity. Its cytotoxic effects on malignant cells have shown an increase in the risk of cardiotoxicity, hepatoxicity, renal insufisance. Antioxydants have been explored for both their cancer preventive properties and chemodulatory of DOX toxicity. Resveratrol (RSV) is a polyphenolic constituent of several dietary mainly of grapes and wine origin recently its anticancer potential has been extensively explored, revealing its anti-proliferative effect on different cancer cell lines, both in vitro and in vivo. RSV is also known to have modulatory effects on cell apoptosis, migration and growth via various signaling pathways. Though, RSV possesses great medicinal value, its applications as a therapeutic drug is limited. Problems like low oral bioavailability and poor aqueous solubility make RSV an unreliable candidate for therapeutic purposes. Additionally, the rapid gastrointestinal digestion of RSV is also a major barrier for its clinical translation. Hence, to overcome these disadvantages RSV-based nanodelivery systems have been considered in recent times. Nanodelivery systems of RSV have shown promising results in its uptake by the epithelial system as well as enhanced delivery to the target site. Herein we have tried to bring new new insights into the molecular mechanisms of DOX toxicity with respect to DNA damage, free radicals and whether RSV can be a playmaker as chemodulatory of DOx.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"30 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2017-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83329557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-04-28DOI: 10.4172/2329-6771.1000192
O. Bajenova, E. Tolkunova, S. Koshkin, S. Malov, P. Thomas, A. Tomilin, S. O’Brien
Clinical and experimental data suggest that carcinoembryonic antigen (CEA, CD66e, CEACAM-5) plays a key role in the formation of hepatic metastasis from colorectal and other types of epithelial cancers. The molecular events involved in CEA-induced metastasis have yet to be defined. Our group first cloned the gene (CEAR) for CEA-binding protein from the surface of fixed liver macrophages, (Kupffer cells). In this study to further elucidate the role of CEAR in colorectal cancer progression, its expression in colorectal cancer cells was suppressed by short hairpin RNAs (shRNAs) in CEA-overexpressing and CEA - negative MIP-101 colorectal cancer cell lines. The data show that targeted suppression of endogenous CEAR in tumor cells resulted in changes in cell invasiveness. RT-PCR data indicated reduced levels of E-cadherin, Snail, MMP-2, and Oct-4 in the clones with suppressed CEAR suggesting a role in the epithelial mesenchymal transition. The comparative analysis of tumorigenic activity to the liver of the cell lines with suppressed CEAR has also been conducted using an intrasplenic injection model in immuno-deficient mice. This data shows a decrease in tumor progression associated with CEAR suppression. In summary the results of this study revealed a novel role for CEAR gene in the regulation of colorectal cancer cell invasiveness and progression.
{"title":"The Role of the Carcinoembryonic Antigen Receptor in Colorectal Cancer Progression","authors":"O. Bajenova, E. Tolkunova, S. Koshkin, S. Malov, P. Thomas, A. Tomilin, S. O’Brien","doi":"10.4172/2329-6771.1000192","DOIUrl":"https://doi.org/10.4172/2329-6771.1000192","url":null,"abstract":"Clinical and experimental data suggest that carcinoembryonic antigen (CEA, CD66e, CEACAM-5) plays a key role in the formation of hepatic metastasis from colorectal and other types of epithelial cancers. The molecular events involved in CEA-induced metastasis have yet to be defined. Our group first cloned the gene (CEAR) for CEA-binding protein from the surface of fixed liver macrophages, (Kupffer cells). In this study to further elucidate the role of CEAR in colorectal cancer progression, its expression in colorectal cancer cells was suppressed by short hairpin RNAs (shRNAs) in CEA-overexpressing and CEA - negative MIP-101 colorectal cancer cell lines. The data show that targeted suppression of endogenous CEAR in tumor cells resulted in changes in cell invasiveness. RT-PCR data indicated reduced levels of E-cadherin, Snail, MMP-2, and Oct-4 in the clones with suppressed CEAR suggesting a role in the epithelial mesenchymal transition. The comparative analysis of tumorigenic activity to the liver of the cell lines with suppressed CEAR has also been conducted using an intrasplenic injection model in immuno-deficient mice. This data shows a decrease in tumor progression associated with CEAR suppression. In summary the results of this study revealed a novel role for CEAR gene in the regulation of colorectal cancer cell invasiveness and progression.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"6 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2017-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87234853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-04-03DOI: 10.4172/2329-6771.1000191
I. Stratulat
The Chernobyl accident that occurred 30 years ago was one of the worst nuclear disasters ever. Although it’s effects have been the subject of several articles, the role of its repercussions in the etiology of hematological disorders is not clearly revealed. Studies have shown a causal relationship between radiation exposure and the incidence of thyroid cancers but in the case of acute lymphoblastic leukemia a correlation could not have been made. However, due to its increasing incidence, there seems to be differences between adult and in utero exposure. Through its geographical position, Romania was affected especially in the North East region. We present the case of acute lymphoblastic leukemia of a patient from Iasi with exposure during pregnancy, post-partum period and the effects on her and the fetus.
{"title":"The Chernobyl and ItâÂÂs Long Term Consequence: Clinical Cases of Leukemia","authors":"I. Stratulat","doi":"10.4172/2329-6771.1000191","DOIUrl":"https://doi.org/10.4172/2329-6771.1000191","url":null,"abstract":"The Chernobyl accident that occurred 30 years ago was one of the worst nuclear disasters ever. Although it’s \u0000 effects have been the subject of several articles, the role of its repercussions in the etiology of hematological \u0000 disorders is not clearly revealed. Studies have shown a causal relationship between radiation exposure and the \u0000 incidence of thyroid cancers but in the case of acute lymphoblastic leukemia a correlation could not have been \u0000 made. However, due to its increasing incidence, there seems to be differences between adult and in utero exposure. \u0000 Through its geographical position, Romania was affected especially in the North East region. We present the case of \u0000 acute lymphoblastic leukemia of a patient from Iasi with exposure during pregnancy, post-partum period and the \u0000 effects on her and the fetus.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73777917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-30DOI: 10.4172/2329-6771.1000190
J. Molinos, Antonio Cobo Molinos
The tumor of unknown origin constitutes 3-7% of the cancers studied and is one of the 10 most frequent cancer diagnoses. It is a malignant tumor whose first origin or identification is not done in the clinical history, in the clinical exploration or in the complementary studies. At present, the effort in the primary search for the origin of the cancer that will be directed at specifying these entities and recognizing them as soon as possible is arduous. Today we have several techniques among which we highlight immunohistochemistry, molecular biology and radiodiagnosis that greatly facilitate the work of the clinician in detecting the origin of tumors, although none of them is conclusive.
{"title":"Approximation to the Patient with Tumor of Unknown Origin","authors":"J. Molinos, Antonio Cobo Molinos","doi":"10.4172/2329-6771.1000190","DOIUrl":"https://doi.org/10.4172/2329-6771.1000190","url":null,"abstract":"The tumor of unknown origin constitutes 3-7% of the cancers studied and is one of the 10 most frequent cancer diagnoses. It is a malignant tumor whose first origin or identification is not done in the clinical history, in the clinical exploration or in the complementary studies. At present, the effort in the primary search for the origin of the cancer that will be directed at specifying these entities and recognizing them as soon as possible is arduous. Today we have several techniques among which we highlight immunohistochemistry, molecular biology and radiodiagnosis that greatly facilitate the work of the clinician in detecting the origin of tumors, although none of them is conclusive.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"75 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2017-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86407052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-06DOI: 10.4172/2329-6771.1000187
Alex, R. Grigorescu
Introduction: Lung cancer is responsible for the highest mortality caused by malignant solid tumors. Chemotherapy remains one of the most important modality of treatment. Methods: This retrospective study analyzed the records of 42 patients’ treatment with pemetrexed, used in second, third and fourth line chemotherapy for advanced non-squamous non-small cell cancer (NSCLC). Kaplan Meier curve was used for calculation of overall survival. Results: The median overall survival in the second-line was 10 months and in third- and fourth-line was 6.5 months. Discussion: We discuss the similar study with pemetrexed in mono-chemotherapy or combination, study with similar results. Also we make a reference to the new therapy with best results but with much higher cost and effective only for a part of patients. Conclusions: This result and other results presented in similar studies encourage us to recommend pemetrexed in the third and fourth line chemotherapy for well-selected patients.
{"title":"Pemetrexed in Third and Fourth Line Chemotherapy for Non Squamous Non Small-Cell Lung Cancer","authors":"Alex, R. Grigorescu","doi":"10.4172/2329-6771.1000187","DOIUrl":"https://doi.org/10.4172/2329-6771.1000187","url":null,"abstract":"Introduction: Lung cancer is responsible for the highest mortality caused by malignant solid tumors. Chemotherapy remains one of the most important modality of treatment. Methods: This retrospective study analyzed the records of 42 patients’ treatment with pemetrexed, used in second, third and fourth line chemotherapy for advanced non-squamous non-small cell cancer (NSCLC). Kaplan Meier curve was used for calculation of overall survival. Results: The median overall survival in the second-line was 10 months and in third- and fourth-line was 6.5 months. Discussion: We discuss the similar study with pemetrexed in mono-chemotherapy or combination, study with similar results. Also we make a reference to the new therapy with best results but with much higher cost and effective only for a part of patients. Conclusions: This result and other results presented in similar studies encourage us to recommend pemetrexed in the third and fourth line chemotherapy for well-selected patients.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"115 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87956775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-27DOI: 10.4172/2329-6771.1000186
Sidy Ka, D. Diouf, Rokhaya Niang, A. Diallo, M. Dieng, P. M. Gaye, A. Dem
Sidy KA1*, Doudou Diouf2, Rokhaya Desirée Niang2, Adja Coumba Diallo1, Mamadou Moustapha Dieng3, Pape Macoumba Gaye3 and Ahmadou Dem1 1Department of Surgical oncology, Joliot Curie Cancer Institute, Dakar, Senegal 2Depatment of Medical oncology, Joliot Curie Cancer Institute, Dakar, Senegal 3Department of Radiotherapy, Joliot Curie Cancer Institute, Dakar, Senegal *Corresponding author: Sidy KA, Surgical oncologist, Joliot Curie Cancer Institute, Dakar, Senegal, Tel: +33 01 56 24 55 00; E-mail: kasidy@hotmail.com
{"title":"Role of Specific Cancer Treatments in Pain Management","authors":"Sidy Ka, D. Diouf, Rokhaya Niang, A. Diallo, M. Dieng, P. M. Gaye, A. Dem","doi":"10.4172/2329-6771.1000186","DOIUrl":"https://doi.org/10.4172/2329-6771.1000186","url":null,"abstract":"Sidy KA1*, Doudou Diouf2, Rokhaya Desirée Niang2, Adja Coumba Diallo1, Mamadou Moustapha Dieng3, Pape Macoumba Gaye3 and Ahmadou Dem1 1Department of Surgical oncology, Joliot Curie Cancer Institute, Dakar, Senegal 2Depatment of Medical oncology, Joliot Curie Cancer Institute, Dakar, Senegal 3Department of Radiotherapy, Joliot Curie Cancer Institute, Dakar, Senegal *Corresponding author: Sidy KA, Surgical oncologist, Joliot Curie Cancer Institute, Dakar, Senegal, Tel: +33 01 56 24 55 00; E-mail: kasidy@hotmail.com","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74695143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：